(Q38106157)

28 August 2017

title

Leukaemias into the 21st century. Part 2: the chronic leukaemias (English)

1 reference

28 August 2017

1 reference

J Gibson

1

1 reference

28 August 2017

H J Iland

2

1 reference

28 August 2017

S R Larsen

3

1 reference

28 August 2017

C M S Brown

4

1 reference

28 August 2017

D E Joshua

5

1 reference

28 August 2017

publication date

1 May 2013

1 reference

Internal Medicine Journal

28 August 2017

published in

1 reference

28 August 2017

volume

43

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

484-494

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

28 August 2017

cites work

1 reference

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

21 January 2018

1 reference

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

21 January 2018

1 reference

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

21 January 2018

1 reference

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

21 January 2018

1 reference

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

21 January 2018

1 reference

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

21 January 2018

1 reference

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

21 January 2018

1 reference

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities

21 January 2018

1 reference

Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia

21 January 2018

1 reference

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

Novel insights into the biology of CLL.

21 January 2018

1 reference

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells

21 January 2018

1 reference

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.

21 January 2018

1 reference

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

21 January 2018

1 reference

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

21 January 2018

1 reference

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

21 January 2018

1 reference

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

21 January 2018

1 reference

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

21 January 2018

1 reference

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/IMJ.12135

1 reference

28 August 2017

1 reference